Best of ASCO - 2014 Annual Meeting

 

Welcome

Advanced Disease

Melanoma/Skin Cancers

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
42-month follow-up of sonidegib efficacy and safety in advanced basal cell carcinoma: Final analysis from BOLT.

Michael Robert Migden

9551

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

Georgina V. Long

9503

5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.

Omid Hamid

9516

A novel, open-access data commons for improved disease management in patients (pts) with Merkel cell carcinoma (MCC).

Zhen Su

e21544

A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma.

Adi Diab

9515

A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma.

Amod Sarnaik

TPS9595

A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic mucosal melanoma.

Jun Guo

9528

A phase II study of JS001, a humanized PD-1 mAb, in patients with advanced melanoma in China.

Zhihong Chi

9539

A phase II study of study of bevacizumab (BEV) in combination with atezolizumab (ATEZO) in pts (pts) with untreated melanoma brain metastases (BEAT-MBM).

Gustavo Schvartsman

TPS9598

A randomized phase Ib/II study of the selective small molecule axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma.

Oddbjorn Straume

9548

A randomized phase II study of anti-PD1 antibody [MK-3475 (Pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605).

Jason J. Luke

TPS9599

A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP): Canadian Clinical Trials Group study (CCTG) ME.13.

Tara D. Baetz

TPS9600

Activity of targeted therapy after failure of first-line immunotherapy in BRAF-mutant metastatic melanoma.

Cathy Yi Xia

9532

Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study.

J?Rgen C. Becker

9527

Adverse events of special interest in the phase 3 COLUMBUS study.

Helen Gogas

9567

Alteration of mutant allele frequency in visceral metastases of melanoma.

Viktória Doma

e21528

Analysis of the kinetics and effects of vemurafenib (V) + cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFmM): Implications for combination with immunotherapy.

Suthee Rapisuwon

9559

Angiogenesis characteristics in benign and malignant melanocytic skin tumors.

Viktoria V. Pozdnyakova

e21529

Anti-PD1 (muDX 400) therapy given after radiation has greatest impact on (CD8+ Tim3- CD73+) stem cell like cells: Implications for improved clinical trial design incorporating radiation and anti-PD1.

Tahseen Nasti

e21525

Association between hospital volume and overall survival (OS) of stage 3 and 4 cutaneous malignant melanoma (MMel).

Anuhya Kommalapati

9524

Association of body mass index (BMI) with overall survival (OS) in metastatic melanoma (MM) patients (pts) treated with combined anti-CTLA4 + anti-PD1.

Jennifer Leigh McQuade

9562

BRAF/MEK inhibition in melanoma patients with rare BRAF mutations.

Jessica Cecile Hassel

9542

Characterization and spatial localization of the tumor immune microenvironment in metastatic uveal melanoma.

Kimberly Mayumi Komatsubara

9570

Characterization of complete responders to combination nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with advanced, unresectable melanoma.

Allison Betof Warner

9552

Chemoimmunotherapy combination after PD-1 inhibitor failure to improve clinical outcomes in metastatic melanoma patients.

Jesus Vera Aguilera

9558

Clinical and economic outcomes associated with sequential treatment in BRAF mutant advanced melanoma patients.

Ahmad A. Tarhini

9538

Clinical characteristics and outcomes associated with molecular status and treatment with vemurafenib in metastatic melanoma (MM) in a real-world setting: Comparison of four groups.

Dorota Malgorzata Kwapisz

e21558

Clinical experience with talimogene laherparepvec in a melanoma population at a university based cancer center.

Alyssa Hinchman

e21547

Clonal evolution of uveal melanoma metastases.

Jessica Yang

e21534

Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616).

Ari M. Vanderwalde

TPS9597

Comprehensive genomic profiling of advanced Merkel cell carcinoma to reveal insights into immunotherapy response.

Todd Cory Knepper

9523

Cost-effectiveness of new therapies in first-line treatment of advanced melanoma for BRAF mutant patients from a Brazilian private payer perspective.

Joao PsDN Lima

e21556

Cost-effectiveness of new therapies in first-line treatment of advanced melanoma for patients with independent BRAF mutation status from a Brazilian private payer perspective.

Christina Matteucci

e21546

CTLA-4 and PD-1 inhibition in metastatic uveal melanoma: A single center experience.

Vidhya Karivedu

e21548

Dendritic cell based immunotherapy in metastatic uveal melanoma.

Jan Nesselhut

e21526

Detection, molecular profiling and culture of CSF-CTCs in leptomeningeal disease (LMDz) in melanoma.

Peter A. J. Forsyth

e21543

Discontinuation of anti-PD-1 mAb after complete response in advanced melanoma pts.

Philippe Saiag

e21549

Distinct patterns of response and toxicity (tox) by sites of metastases (mets) in patients (pts) treated with ipilimumab combined with PD-1 antibodies (ipi+PD1).

Ines Esteves Domingues Pires Da Silva

9553

Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy.

Paul Nghiem

9506

Economic evaluation of the combination of talimogene laherparepvec (T-vec) plus ipilimumab (T-vec+Ipi) versus ipilimumab (Ipi) in patients (pts) with advanced unresectable melanoma.

Abdulaali Almutairi

e21545

Effects of sonidegib dose reduction or delay in locally advanced basal cell carcinoma: 42-month data from BOLT.

Karl D. Lewis

9573

Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanoma.

Robert Hans Ingemar Andtbacka

9541

Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study.

Brigitte Dreno

9522

Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody.

Sanjiv S. Agarwala

9530

Elderly patient’s tolerance and efficacy for MAP-kinase inhibitors in a French melanoma real-life cohort.

Ondine Becquart

e21536

Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

Georgina V. Long

108

Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.

Adil Daud

9511

EZH2 copy number gain as a therapeutic target in mucosal melanoma.

Huan Yu

e21530

Factors predicting the use of immunotherapy for patients with advanced melanoma.

Richard Wayne Joseph

9571

HORIZON: A French descriptive cohort of 663 patients treated for melanoma with pembrolizumab with a focus on the mucosal subgroup (n=59).

Caroline Dutriaux

9563

Horizon: An ambispective study of 663 patients who initiated pembrolizumab for advanced melanoma within the French early access program.

Nicolas Meyer

e21519

Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.

Helen Clare Dearden

9545

Identification of radiation induced exosomes as a potential in situ vaccine for melanoma growth delay.

Mohammad Khurram Khan

e21535

Immune checkpoint inhibition (ICI) in advanced cutaneous squamous cell carcinoma (cSCC): Clinical response and correlative biomarker analysis.

Jong Chul Park

9564

Immune checkpoint inhibitor (ICI) treatment in advanced melanoma (aMel) patients (pts) with renal or hepatic dysfunction (dysf): Real-world patient characteristics and outcomes.

Susan Spillane

9569

Immune checkpoint inhibitors and stereotactic radiosurgery (SRS) in melanoma brain metastases.

Charlotte Fenioux

e21523

Immune-related adverse events (irAEs) with ipilimumab treatment of advanced melanoma: A single institution review.

Caitlyn Nicole Myrdal

e21533

Immunotherapy efficacy and safety in elderly cutaneous malignancy patients.

Nicole Carreau

e21524

Immunotherapy in metastatic melanoma: When is it safe to stop?

Jemma Longley

e21518

Impact of simultaneous radiotherapy in melanoma patients treated with pembrolizumab in the French early access program.

Philippe Saiag

9555

Interim analysis of a prospective, randomized, double blind, placebo controlled, phase IIb trial of the TLPLDC vaccine to prevent recurrence in resected stage III or IV melanoma patients.

John William Myers

9525

Ipilimumab and radiation in patients with unresectable melanoma brain metastases: A multicenter, open label, phase-2, Spanish Melanoma Group (GEM) study (NCT-2013-001132-22).

Jose A. Lopez-Martin

9546

Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicenter, open label, phase 2 trial.

Laurent Mortier

9520

Ipilimumab with anti PD-1 (nivovlumab or pembrolizumab) after progression on first line anti-PD-1 therapy for advanced melanoma.

Inderjit Mehmi

e21552

Long-term survival in metastatic uveal melanoma (MUM).

Sophie Piperno Neumann

e21501

Management of patients with metastatic melanoma in the cancer immunotherapy era: A simulation-based assessment of medical oncologists.

Tara Herrmann

e21512

Methylation among members of the PI3K/AKT/mTOR pathway in melanoma brain and extracerebral metastases.

Friedegund Elke Meier

e21515

Multicenter phase I/IIa study using T cell receptor gene therapy in metastatic melanoma.

Maartje W. Rohaan

TPS9602

Multi-spatial whole-lesion molecular heterogeneity of an immunotherapy-resistant metastatic melanoma.

Akash Mitra

9568

Mutation frequencies in a gene panel among primary tumors and metastases in patients with melanoma.

Antonella Manca

e21554

Neoadjuvant (neo) immune checkpoint blockade (ICB) in patients (Pts) with high-risk resectable metastatic melanoma (MM).

Rodabe Navroze Amaria

9510

Neoadjuvant therapy in advanced melanoma.

Shalana O'Brien

e21555

Next-generation-sequencing of advanced melanoma: Which genetic alterations have an impact on systemic therapy response?

Andrea Forschner

e21557

Objective response rate (ORR) and time to treatment failure (TTF) for BRAF v600 mutated metastatic melanoma (BRAF+ MM) patients receiving first-line (1L) targeted therapy (TT) or immuno-oncology (I-O) agents at US-based community oncology practices.

Jason J. Luke

e21516

Objective response rate (ORR) and time to treatment failure (TTF) for BRAF v600 mutated metastatic melanoma (BRAF+ MM) patients receiving first-line (1L) treatment with dabrafenib/trametinib (D+T) v ipilimumab/nivolumab (I+N) and nivolumab or pembrolizumab (N/P) monotherapy at US-based community oncology practices.

Bruce A. Feinberg

e21538

Off treatment survival (OTS) in patients (pts) with advanced melanoma after anti-PD1 therapy.

Shelly Ann Christiansen

9554

Outcomes of elderly treated with pembrolizumab for metastatic melanoma comparing with younger patients.

Caroline Dutriaux

e21508

Outcomes of metastatic melanoma (MM) patients (pts) after discontinuation of anti-Programmed-Death 1 (PD1) therapy without disease progression.

Gustavo Schvartsman

9549

Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.

Reinhard Dummer

9504

Patient preferences for clinical attributes of metastatic melanoma treatment with targeted therapy and immunotherapy.

Carol Mansfield

e21511

Pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin: Interim results of the phase 2 CARSKIN trial.

Eve Maubec

9534

Perilesional edema and blood vessel characteristics in brain metastases and implications for treatment with immune therapy.

Thuy Tran

9572

Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data.

Taofeek Kunle Owonikoko

9557

Phase 1 study to evaluate safety and efficacy of nivolumab (nivo) + ipilimumab (ipi) + external beam radiotherapy (RT) in patients with metastatic melanoma.

Michael A. Postow

9550

Phase 1b results of avelumab in patients (pts) with previously treated metastatic melanoma enrolled in the JAVELIN Solid Tumor trial, including updated subgroup analyses.

Ulrich Keilholz

e21531

Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.

Antoni Ribas

9513

Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.

Yousef Zakharia

9512

Phase I/II study of the PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.

Hussein Abdul-Hassan Tawbi

TPS9596

Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma (cSCC).

Ragini Reiney Kudchadkar

9543

Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel).

Daniel Olson

9514

Prediction of response and toxicity to immune checkpoint inhibitor therapies (ICI) in melanoma using deep neural networks machine learning.

Zarmeena Dawood

9529

Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC).

Danny Rischin

9519

Prognostic markers for progression free survival (PFS) to anti PD-1 therapies in metastatic melanoma.

Umang Swami

e21527

Progression-free(PFS) and overall survival (OS) in treatment of BRAF mutation-positive metastatic melanoma: Bayesian network meta-analysis.

Mok Oh

e21532

Radioembolization for treatment of uveal melanoma hepatic metastasis: Results of a phase II, single institution, prospective trial.

Carin F. Gonsalves

9535

Real world data on the use and sequence of targeted and immuno-oncology drugs in metastatic melanoma (MM) patients (pts).

Carolina Ortiz

e21541

Real-world utilization and patient outcomes associated with pembrolizumab in advanced melanoma in US academic centers and affiliated satellite clinics.

Richard Wayne Joseph

e21500

Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings.

Takami Sato

9521

Relapse after cessation of PD-1 based therapy for complete responders in metastatic melanoma.

Khang Nguyen

9536

Relationship between pre-treatment organ-specific tumor burden (TB) and response to immunotherapy in advanced melanoma (MEL).

Ryan Campbell Massa

e21507

Response assessment to anti-CTLA4 or/and anti-PD1 immunotherapy in mucosal melanomas.

Antoine Moya-Plana

e21517

Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT#02965716).

Siwen Hu-Lieskovan

TPS9603

Safety and efficacy of combining pembrolizmumab and dose escalation/fraction de-escalation SRS for melanoma and NSCLC brain metastasis: Preliminary results from arm a of a prospective pilot trial.

Mohammad Khurram Khan

e21542

Safety and preliminary activity data from a single center phase II study of triplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [trident] in patients (Pts) with BRAF-mutated metastatic melanoma (MM).

Hussein Abdul-Hassan Tawbi

9560

Second-line avelumab treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from a global expanded access program (EAP).

John Walker

9537

Serum protein predictors of long term survival from combined ipilimumab and nivolumab therapy in metastatic melanoma patients.

Krisztian Homicsko

e21513

Sex differences in tolerability to Anti-PD1 therapy: Are we all equal?

Narjust Duma

9547

SMO mutations do not seem to drive multifocal relapse of locally advanced basal cell carcinoma after vismodegib discontinuation.

Nicole Basset Seguin

e21559

Survivorship experience for patients (pts) with metastatic melanoma (MM) on immunotherapy (IT).

Julia Elizabeth Lai-Kwon

e21503

Survivorship experience for patients (pts) with metastatic melanoma (MM) on long-term targeted therapy (TT).

Chloe Chia Hoey Khoo

9556

Systemic therapy in patients with advanced cutaneous squamous cell carcinoma of the head and neck.

Samantha Tam

e21550

The population-based impact of new therapeutic eras on outcomes in advanced melanoma.

Jordan Doherty

e21553

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who have received PD-1 based therapy.

Karim Saab

9540

Treatment of metastatic uveal melanoma (mUM) directed by a comprehensive molecular tumour analysis program (CMTA).

Serge Leyvraz

9566

Treatment-free survival (TFS), a novel outcome applied to immuno-oncology (IO) agents in advanced melanoma (AM).

Meredith M. Regan

9531

Trial in progress: A phase 2 study of intratumor pil-12 plus electroporation in combination with intravenous pembrolizumab in patients with stage III/IV mealanoma progressing on either pembrolizumab or nivolumab treatment (PISCES).

Robert Hans Ingemar Andtbacka

TPS9601

Tumor mutational burden, clinical features, and outcomes to PD-1 mono- and combination therapy in patients with cutaneous and unknown primary melanoma.

Alexander Noor Shoushtari

9561

Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.

Paul Nghiem

9507

Utility of 1-year FDG-PET (PET) to determine outcomes from anti-PD-1 (PD1) based therapy in patients (pts) with metastatic melanoma (MM).

Aaron C. Tan

9517